<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054843</url>
  </required_header>
  <id_info>
    <org_study_id>Afamin in GDM</org_study_id>
    <nct_id>NCT04054843</nct_id>
  </id_info>
  <brief_title>Afamin in Gestational Diabetes Mellitus</brief_title>
  <official_title>Afamin Levels in First Trimester Pregnancies With Gestational Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study includes pregnancies in 11 to 14 th gestational weeks. Investigators will sample
      maternal plasma in the first trimester and analyze maternal plasma afamin values. All these
      women will then be screened by two step OGTT. Investigators will compare afamin levels in GDM
      and control groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Gestational diabetes mellitus (GDM) is an endocrinopathy that occurs during
      pregnancy, and presents several clinical findings together with increased blood glucose
      levels. The frequency of GDM differs, while the incidence of the disease in Turkey is
      reported to be 7%. Most of the societies recommend screening all women with or without any
      risk factors in terms of GDM. The definitive diagnosis is made via oral glucose challenge
      test (OGTT). Early diagnosis and treatment are the key points to improve maternal and fetal
      outcomes. Different biomarkers are studied regarding GDM diagnosis starting from first
      trimester. However, there is not a worldwide accepted biomarker for defining the high risk
      group to the date. Afamin is known as an important indicator of oxidative stress. Moreover,
      oxidative stress itself is strongly associated with insulin resistance and obesity which are
      responsible from GDM pathogenesis.

      Objective To investigate the association between first trimester maternal plasma afamin
      levels and GDM. Also, investigators aimed to understand the role of afamin for the prediction
      of GDM in this study.

      Methods This is an observational prospective cohort study conducted in Department of
      Perinatology, Etlik Zubeyde Hanim Women's Health Care, Training and Research Hospital,
      University of Health Sciences, Ankara, Turkey. During 11 and 14 weeks of gestational,
      maternal blood will be obtained from eligible pregnant women, and samples will be stored at
      -80 oC. Informed written consent will be obtained from participants. Between 24th and 28th
      gestational weeks, all these women will be screened by two step OGTT. Then, afamin levels
      will be compared in GDM and control groups. Exclusion criteria are; multiple pregnancy, fetal
      anomalies, pregestational diabetes, underlying chronic diseases (hypertension, thyroid
      dysfunction, other endocrinopathies, autoimmune disorders), age &lt;18 or &gt; 35 years, fasting
      glucose level &gt; 105 mg/dL or random glucose level &gt; 200 mg/dL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal plasma afamin levels In first trimester GDM prediction</measure>
    <time_frame>6 months</time_frame>
    <description>The predictive value of first trimester maternal plasma afamin levels for the diagnosis of gestational diabetes mellitus in comparison with two step OGTT</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Gestational Diabetes Mellitus in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Gestational diabetes mellitus</arm_group_label>
    <description>First trimester pregnancies with gestational diabetes mellitus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>First trimester healthy pregnancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Afamin</intervention_name>
    <description>Plasma maternal afamin levels</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Gestational diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women within 11 and 14 weeks of gestational weeks
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  singleton pregnancy,

          -  having no fetal anomalies

          -  having no pregestational diabetes

          -  having no underlying chronic diseases (hypertension, thyroid dysfunction, other
             endocrinopathies, autoimmune disorders)

          -  age &gt;18 or &lt; 35 years

          -  fasting glucose level &lt; 105 mg/dL

        Exclusion Criteria:

          -  multiple pregnancy

          -  fetal anomalies

          -  pregestational diabetes

          -  underlying chronic diseases (hypertension, thyroid dysfunction, other
             endocrinopathies, autoimmune disorders)

          -  age &lt;18 or &gt; 35 years

          -  fasting glucose level &gt; 105 mg/dL or random glucose level &gt; 200 mg/dL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Aykan Yucel, Professor</last_name>
    <phone>+905323851110</phone>
    <email>aykanyucel@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dilek Sahin, Professor</last_name>
    <phone>+905324675019</phone>
    <email>dilekuygur@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aykan Yucel, Professor</last_name>
      <phone>+905323851110</phone>
      <email>aykanyucel@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dilek Sahin, Professor</last_name>
      <phone>+905324675019</phone>
      <email>dilekuygur@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aykan Yucel, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dilek Sahin, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hasan Eroglu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuray Yazıhan, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sevginur Aktas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Aykan Yucel, Professor, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

